SB-269970

SB-269970
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
Formula C18H28N2O3S
Molar mass 352.490 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

SB-269970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It is believed to act as a selective 5-HT7 receptor antagonist (EC50 = 1.25 nM) (or possibly inverse agonist). A subsequent study in guinea pig at 10 uM showed that it also blocks the α2-adrenergic receptor activity.[1][2][3] The significant difference in test concentrations, however, confirms the selectivity of SB-269970 for the 5-HT7 receptor.

SB-269970 is used to study the 5-HT7 receptors which are thought to be involved in the function of several areas of the brain such as the hippocampus and thalamus,[4] and regulation of dopamine release in the ventral tegmental area.[5] Possible therapeutic uses for SB-269970 and other 5-HT7 antagonists include the treatment of anxiety and depression,[6][7] and nootropic effects have also been noted in animal studies.[8][9]

References

  1. ↑ Mahé C; Loetscher E; Feuerbach D; Müller W; Seiler MP; Schoeffter P (2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". Eur. J. Pharmacol. 495 (2–3): 97–102. PMID 15249157. doi:10.1016/j.ejphar.2004.05.033.
  2. ↑ Lovell PJ, Bromidge SM, Dabbs S, et al. (2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970)". J. Med. Chem. 43 (3): 342–5. PMID 10669560. doi:10.1021/jm991151j.
  3. ↑ Foong JP; Bornstein JC. (2009). "5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig". Neuroreport. 20 (3): 325–330. PMID 19190523. doi:10.1097/WNR.0b013e3283232caa.
  4. ↑ Thomas DR, Hagan JJ (2004). "5-HT7 receptors". Current drug targets. CNS and neurological disorders. 3 (1): 81–90. PMID 14965246. doi:10.2174/1568007043482633.
  5. ↑ Mnie-Filali O, Dahan L, Zimmer L, Haddjeri N (2007). "Effects of the serotonin 5-HT(7) receptor antagonist SB-269970 on the inhibition of dopamine neuronal firing induced by amphetamine". European Journal of Pharmacology. 570 (1–3): 72–6. PMID 17586491. doi:10.1016/j.ejphar.2007.05.037.
  6. ↑ Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG (2005). "5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern". Biological Psychiatry. 58 (10): 831–7. PMID 16018977. doi:10.1016/j.biopsych.2005.05.012.
  7. ↑ Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (2006). "Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression". Neuropharmacology. 51 (3): 578–86. PMID 16828124. doi:10.1016/j.neuropharm.2006.04.017.
  8. ↑ Gasbarri A, Cifariello A, Pompili A, Meneses A (2008). "Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat". Behavioural Brain Research. 195 (1): 164–70. PMID 18308404. doi:10.1016/j.bbr.2007.12.020.
  9. ↑ Liy-Salmeron G, Meneses A (2008). "Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model". Hippocampus. 18 (9): 965–74. PMID 18570192. doi:10.1002/hipo.20459.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.